Penn spinout BlueWhale Bio comes out of stealth mode

In September 2023, Penn spinout BlueWhale Bio surfaced with a mission to overhaul cell therapy production.

The Philadelphia-based company uncloaked last week with news that it has raised $18 million in seed financing, led by the ventures arm of Danaher Corporation with contributions from Novalis LifeSciences and Marshall Wace.

BlueWhale’s goal is to develop a technology platform and product portfolio that have the potential to bring the benefits of cell therapy to more patients in a way that is quicker and requires lower costs.

Read more about BlueWhale here:

Skip to content